Marshall A Corson
Overview
Explore the profile of Marshall A Corson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
1708
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ning X, Villet O, Ge M, Sekhar L, Corson M, Tylee T, et al.
Ther Hypothermia Temp Manag
. 2014 Dec;
5(1):40-7.
PMID: 25514569
Many therapeutic hypothermia recommendations have been reported, but the information supporting them is sparse, and reveals a need for the data of target therapeutic hypothermia (TTH) from well-controlled experiments. The...
2.
Corson M
Ther Adv Cardiovasc Dis
. 2010 Jul;
4(4):241-8.
PMID: 20660537
Despite a reduction in cardiovascular risk conferred by therapies that modify circulating lipids, a need remains for novel treatments to further decrease the occurrence of complications of atherosclerotic cardiovascular diseases....
3.
Cushman W, Evans G, Byington R, Goff Jr D, Grimm Jr R, Cutler J, et al.
N Engl J Med
. 2010 Mar;
362(17):1575-85.
PMID: 20228401
Background: There is no evidence from randomized trials to support a strategy of lowering systolic blood pressure below 135 to 140 mm Hg in persons with type 2 diabetes mellitus....
4.
Pop-Busui R, Evans G, Gerstein H, Fonseca V, Fleg J, Hoogwerf B, et al.
Diabetes Care
. 2010 Mar;
33(7):1578-84.
PMID: 20215456
Objective: Intensive therapy targeting normal blood glucose increased mortality compared with standard treatment in a randomized clinical trial of 10,251 participants with type 2 diabetes at high-risk for cardiovascular disease...
5.
Corson M
Curr Cardiol Rep
. 2009 Oct;
11(6):452-9.
PMID: 19863870
Although assessment of traditional coronary heart disease risk factors can often stratify individuals into low- or high-risk categories, additional means are needed to more precisely classify people clinically defined as...
6.
Riley R, Corson M
IDrugs
. 2009 Oct;
12(10):648-55.
PMID: 19790016
Darapladib, under development by GlaxoSmithKline plc, is a novel inhibitor of lipoprotein-associated phospholipase A2 (PLA2), an enzyme that may link lipid metabolism with inflammation, leading to the increased stability of...
7.
Moorman A, Corson M, Goldberger Z
Am J Med
. 2009 Sep;
122(10):913-5.
PMID: 19786159
No abstract available.
8.
9.
Davidson M, Corson M, Alberts M, Anderson J, Gorelick P, Jones P, et al.
Am J Cardiol
. 2008 Jul;
101(12A):51F-57F.
PMID: 18549872
A consensus panel was formed to review the rapidly emerging literature on the vascular-specific inflammatory marker lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and to update recommendations for the appropriate use of this...
10.
Corson M, Jones P, Davidson M
Am J Cardiol
. 2008 Jul;
101(12A):41F-50F.
PMID: 18549871
A substantial body of peer-reviewed studies has been published validating the role of inflammation in atherogenesis and supporting lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) as a cardiovascular risk marker independent of and...